News

International collaboration to develop bioprinted tissues treatments for kidney disease

31 May 2019
Prof Melissa Little from MCRI, welcomes the collaboration with Organovo, to bioprint kidney tissue.
Professor Melissa Little at the Murdoch Childrens Research Institute (MCRI), The Royal Children’s Hospital and Ton Rabelink at Universiteit Leiden, Netherlands have today announced a collaboration with Organovo Holdings, Inc. (Organovo), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious adult and pediatric liver diseases.

The project will expand the use of 3D bioprinted stem cell-based therapeutic tissue to applications aimed at treating end-stage renal disease.  This multi-organizational effort integrates Organovo’s leading bioprinting platform with MCRI’s advanced stem cell differentiation technology and LUMC’s cell lines and clinical expertise.  The collaboration has been made possible through generous funding from Stem Cells Australia and CSL Behring Australia.

“Partnerships with world-class institutions can accelerate groundbreaking work in finding cures for critical unmet disease needs and the development of implantable therapeutic tissues," said Taylor J. Crouch, CEO, Organovo. “This collaboration is another important step in this direction.  With the devoted support of Stem Cells Australia and CSL Behring Australia, leading researchers are able to leverage Organovo’s powerful bioprinting technology platform to achieve significant breakthroughs.”

“We have continued to advance and refine our proprietary approach for modeling human kidney tissue from stem cells,” remarked Professor Melissa Little, Theme Director of Cell Biology at Murdoch Childrens Research Institute. 

“By using Organovo’s bioprinter, we can create a stem-cell based therapeutic tissue that may serve as an important step in treating kidney disease.  We are grateful to Organovo, Stem Cells Australia and CSL Behring for their ongoing support of our work in regenerative medicine.”

“The partnership between Organovo and Professor Little is an outstanding example the translational partnerships fostered by the Stem Cells Australia MRFF accelerated research program” stated Professor Christine Wells, deputy program lead, Stem Cells Australia.

“The goals of the program are to link experts in bioengineering stem cell biology and clinical research to address therapeutic gaps in areas of critical unmet need.”